检索结果-南通市图书馆

中华医学杂志(英文版) 2024年第16期137卷 1991-1992页

作者： Li Hang Cheng Hao Lu Qianjin Lai Wei tao xiaohua Encinas Gerardo A. Vyas Shefali Wang Bo Luo Xin Li Shiqi Department of Dermatology Peking University First Hospital National Clinical Research Center for Skin and Immune Diseases Beijing China Department of Dermatology Sir Run Run Shaw Hospital Zhejiang University School of Medicine Hangzhou Zhejiang China Department of Dermatology The Second Xiangya Hospital of Central South University Changsha Hunan China Department of Dermatology The Third Affiliated Hospital of Sun Yat-sen University Guangzhou Guangdong China Department of Dermatology Zhejiang Provincial People’s Hospital Hangzhou Medical College Hangzhou Zhejiang China Pfizer S.A. de C.V. Mexico City Mexico Pfizer Inc. New York NY USA Pfizer Investment Co. Ltd Beijing China Pfizer (China) R& D Co. Ltd Shanghai China Pfizer PBG Shanghai China

Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis:A multicenter,randomized,double-blind,placebo-controlled phase 2b trial

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Chinese Medical Journal 2024年第2期137卷 200-208页

作者： Yan Zhao Jianzhong Zhang Bin Yang Jingyi Li Yangfeng Ding Liming Wu Litao Zhang Jinyan Wang Xiaohong Zhu Furen Zhang xiaohua tao Yumei Li Chunlei Zhang Linfeng Li Jianyun Lu Qingchun Diao Qianjin Lu Xiaoyong Man Fuqiu Li Xiujuan Xia Hao Cheng Yingmin Jia Guoqing Zhao Jinchun Yan Bo Chen Department of Dermatology Peking University People’s HospitalBeijing 100044China Department of Dermatology Dermatology HospitalSouthern Medical UniversityGuangzhouGuangdong 510091China Department of Dermatology West China HospitalSichuan UniversityChengduSichuan 610041China Department of Dermatology Shanghai Skin Disease HospitalInstitute of PsoriasisTongji University School of MedicineShanghai 200443China Department of Dermatology Affiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhouZhejiang 310006China Department of Dermatology Tianjin Academy of Traditional Chinese Medicine Affiliated HospitalTianjin 300120China Department of Dermatology Ningbo No.2 HospitalNingboZhejiang 315010China Department of Dermatology The Wuxi Second Affiliated Hospital of Nanjing Medical UniversityWuxiJiangsu 214002China Shandong Provincial Hospital for Skin Diseases&Shandong Provincial Institute of Dermatology and Veneorology Shandong First Medical University&Shandong Academy of Medical SciencesJinanShandong 250022China Center for Plastic&Reconstructive Surgery Department of DermatologyZhejiang Provincial People’s Hospital(Affiliated People’s HospitalHangzhou Medical College)HangzhouZhejiang 310014China Department of Dermatology Affiliated Hospital of Jiangsu UniversityZhenjiangJiangsu 212001China Department of Dermatology Peking University Third HospitalBeijing 100191China Department of Dermatology Beijing Friendship HospitalCapital Medical UniversityBeijing 100050China Department of Dermatology The Third Xiangya Hospital of Central South UniversityChangshaHunan 410013China Department of Dermatology Chongqing Traditional Chinese Medicine HospitalChongqing 400011China Hunan Key Laboratory of Medical Epigenomics Department of DermatologyThe Second Xiangya Hospital of Central South UniversityChangshaHunan 410011China Department of Dermatology The Second Affiliated HospitalZhejiang University School of MedicineHangzhouZhejiang 310009China Departme

Background:Atopic dermatitis(AD)affects approximately 10%of adults ***310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 *** trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe ***:This multicenter,randomized,double-blind,placebo-controlled,phase 2b trial was conducted in 21 medical institutions in China from February to November *** 120 eligible patients were enrolled and randomized(1:1:1)to receive subcutaneous injections of 300 mg CM310,150 mg CM310,or placebo every 2 weeks for 16 weeks,followed by an 8-week follow-up *** primary endpoint was the proportion of patients achieving≥75%improvement in the Eczema Area and Severity Index(EASI-75)score from baseline at week *** and pharmacodynamics were also ***:At week 16,the proportion of EASI-75 responders from baseline was significantly higher in the CM310 groups(70%[28/40]for high-dose and 65%[26/40]for low-dose)than that in the placebo group(20%[8/40]).The differences in EASI-75 response rate were 50%(high ***,95%CI 31%-69%)and 45%(low ***,95%CI 26%-64%),with both P values<***310 at both doses also significantly improved the EASI score,Investigator’s Global Assessment score,daily peak pruritus Numerical Rating Scale,AD-affected body surface area,and Dermatology Life Quality Index compared with ***310 treatment reduced levels of thymus and activation-regulated chemokine,total immunoglobulin E,lactate dehydrogenase,and blood *** incidence of treatment-emergent adverse events(TEAEs)was similar among all three groups,with the most common TEAEs reported being upper respiratory tract infection,atopic dermatitis,hyperlipidemia,and *** severe adverse events were deemed to be attributed to ***:CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tol

关键词： CM310 Moderate-to-severe atopic dermatitis Interleukin-4 receptor alpha Adults

麻黄细辛附子汤对过敏性鼻炎小鼠神经通路的影响

在线全文

学校读者我要写书评

暂无评论

世界中医药 2024年第7期19卷 975-979页

作者：张艺陶晓华刘男男于雪刘敏北京中医药大学中医学院北京100029

目的:探索麻黄细辛附子汤(MXFD)及其拆方对过敏性鼻炎(AR)的作用机制,明确其是否通过2型固有淋巴样细胞(ILC2s)上的神经通路神经调节肽U(NMU)/神经调节肽U受体1(NMUR1)发挥抗过敏作用。方法:C57BL/6J小鼠分别按单味药、两味药、三味药... 详细信息

目的:探索麻黄细辛附子汤(MXFD)及其拆方对过敏性鼻炎(AR)的作用机制,明确其是否通过2型固有淋巴样细胞(ILC2s)上的神经通路神经调节肽U(NMU)/神经调节肽U受体1(NMUR1)发挥抗过敏作用。方法:C57BL/6J小鼠分别按单味药、两味药、三味药组合给药分为7组,使用鸡卵清蛋白(OVA)制备AR模型,造模成功后给予不同组合的中药灌胃治疗14 d。过敏反应行为学评分法评价模型是否成功;免疫荧光双染法检测肺组织中活化T细胞核因子2(NFAT2)的含量;逆转录实时定量聚合酶链式反应(RT-qPCR)检测肺组织中神经调节肽U受体1(NMUR1)的基因表达水平。结果:小鼠造模成功,各组NFAT2、NMUR1基因的表达水平均升高(均P<0.01)。中药治疗后,给药各组过敏反应行为学评分均降低(均P<0.01);NFAT2表达均降低(均P<0.01),麻黄组抑制效果最显著;除辛附组,其他组NMUR1的基因表达水平均降低(均P<0.01),麻附组、细辛组抑制效果最显著。结论:麻黄细辛附子汤可影响NMU/NMUR1通路抑制过敏性鼻炎,麻黄单用在抑制NFAT2环节效果最优,麻黄和附子合用、细辛单用抑制NMUR1表达效果最优。

关键词：麻黄细辛附子汤拆方过敏性鼻炎 2型固有淋巴样细胞神经调节肽U/神经调节肽U受体1通路活化T细胞核因子2 神经调节肽U受体1

婴儿头癣3例及其家属头皮无症状携带同一病原菌

在线全文

学校读者我要写书评

暂无评论

临床皮肤科杂志 2024年第1期53卷 6-9页

作者：江情陶小华罗云鹏樊心怡徐蕊金云江西省皮肤病专科医院真菌科、江西省皮肤病临床医学研究中心、国家皮肤与免疫疾病临床医学研究中心分中心建设单位江西南昌330001

目的:探讨头癣患儿家属的头皮无症状携带情况。方法:取患儿病发及其家属头皮行真菌直接镜检和真菌培养,并分析头癣类型、病原菌特点以及患儿及其家属的病原菌同源性情况。结果:3例头癣患儿包括2例脓癣和1例黑点癣。3例患儿家属(5例)均... 详细信息

目的:探讨头癣患儿家属的头皮无症状携带情况。方法:取患儿病发及其家属头皮行真菌直接镜检和真菌培养,并分析头癣类型、病原菌特点以及患儿及其家属的病原菌同源性情况。结果:3例头癣患儿包括2例脓癣和1例黑点癣。3例患儿家属(5例)均存在头皮无症状携带皮肤真菌,且病原菌均与患儿一致,其中1例为断发毛癣菌,2例为紫色毛癣菌。3例患儿予口服抗真菌药治疗后均治愈。结论:头癣患儿的家属可能存在无症状携带皮肤真菌的可能,不利于头癣疾病流行的防治,应引起关注并及时采取预防或治疗干预。

关键词：头癣无症状携带皮肤真菌儿童

从《神农本草经》谈张仲景运用桃仁的证治特色

在线全文

学校读者我要写书评

暂无评论

中华中医药杂志 2024年第8期39卷 4425-4428页

作者：李冉李志鸣张艺李明周冉冉侯鉴宸陶晓华北京中医药大学中医学院北京100029 北京中医药大学中医文献研究院北京100029

《伤寒杂病论》中所用药物大多本于《神农本草经》,二者一脉相承。《神农本草经》载桃仁主瘀血、血闭瘕、邪气,杀小虫。文章从《神农本草经》原文角度出发,梳理《伤寒杂病论》中所含桃仁的方剂,归纳总结张仲景运用桃仁的证治特色,发现... 详细信息

《伤寒杂病论》中所用药物大多本于《神农本草经》,二者一脉相承。《神农本草经》载桃仁主瘀血、血闭瘕、邪气,杀小虫。文章从《神农本草经》原文角度出发,梳理《伤寒杂病论》中所含桃仁的方剂,归纳总结张仲景运用桃仁的证治特色,发现张仲景运用桃仁在继承经典的基础上又有所开拓。此外,重点对桃仁主邪气这一功效进行论述,认为《神农本草经》所言邪气偏指“鬼邪”致病,以精神神志异常、癥瘕积聚等疑难病为主。这一认识对于更加全面掌握桃仁用药规律、提高临床疗效有所裨益。

关键词：桃仁张仲景《神农本草经》邪气证治特色临床应用

基于知识元理论与临床需求深度融合的中医古籍数智化研究路径和范式

在线全文

学校读者我要写书评

暂无评论

中医杂志 2024年第12期65卷 1201-1207页

作者：杨凤张艺陶晓华李剑峰罗涛常静玲陈健陈丽云戴铭王凤兰陆翔北京中医药大学北京市朝阳区100029 北京邮电大学北京中医药大学东直门医院上海中医药大学广西中医药大学中国中医科学院中国医史文献研究所安徽中医药大学

随着信息技术的迅速发展,中医古籍整理从传统整理、数字化研究转向智能化中医知识服务,以实现中医古籍整理成果与临床需求的深度融合。以临床问题为导向,基于知识元理论,对600种中医古籍实施深度标引和知识挖掘,融合数据库、云平台、知... 详细信息

随着信息技术的迅速发展,中医古籍整理从传统整理、数字化研究转向智能化中医知识服务,以实现中医古籍整理成果与临床需求的深度融合。以临床问题为导向,基于知识元理论,对600种中医古籍实施深度标引和知识挖掘,融合数据库、云平台、知识图谱等技术搭建了中医古籍知识共享服务平台;以脑卒中、心力衰竭、肝硬化、糖尿病四种重大疾病为示范,进行专题文献研究和专病数据库建设,并将数智化研发成果应用于百家医院进行测评反馈。最终,通过“数字化加工+智能化应用”的方式,实现中医古籍与当代临床的双向互动,形成中医古籍知识服务于重大疾病现代防控的路径与范式,为中医古籍的创新性利用提供参考。

关键词：中医古籍知识元数智化知识服务脑卒中心力衰竭肝硬化糖尿病

在线全文

学校读者我要写书评

暂无评论

抵当乌头桂枝汤考

中华中医药杂志 2024年第8期39卷 4084-4087页

作者：李志鸣周冉冉官庆烨侯鉴宸杨凤张艺邱月华陶晓华北京中医药大学中医学院北京100029 北京中医药大学中医文献研究院北京100029

“抵当乌头桂枝汤”出自《金匮要略》腹满寒疝篇,为治疗表里俱寒之寒疝经典方剂,历来对“抵当”二字的阐释争议颇多,方中乌头剂量亦有阙如。文章综合运用版本学、训诂学等研究方法,通过对比《金匮要略》现存5个主要版本和中医古籍中与... 详细信息

“抵当乌头桂枝汤”出自《金匮要略》腹满寒疝篇,为治疗表里俱寒之寒疝经典方剂,历来对“抵当”二字的阐释争议颇多,方中乌头剂量亦有阙如。文章综合运用版本学、训诂学等研究方法,通过对比《金匮要略》现存5个主要版本和中医古籍中与此方相关文献,认为“抵当”二字当为衍文,北宋校正医书局根据《外台秘要》中讹误的记载,在条文中增补了“抵当”二字,但并未出注;乌头剂量为五枚;附方乌头汤与乌头桂枝汤药物剂量、煎服法各异,因宋代煮散风尚,将汤剂改为散剂时,二者药物组成相同,北宋校正医书局故而将其列为一方,这种较大的改动使得宋代及其之后的不少医家将两方相混淆,两方也逐渐淡化了各自的主治特点。

关键词：《金匮要略》抵当乌头桂枝汤抵当乌头附方乌头汤

How to achieve energy efficiency in buildings without compromising indoor air quality:A case study on enthalpy exchangers

在线全文

学校读者我要写书评

暂无评论

Science China(Technological Sciences) 2024年第9期67卷 2648-2658页

作者： LI Hao ZHANG tao LIU xiaohua Department of Building Science Tsinghua UniversityBeijing 100084China

As a representative heat recovery device,the fixed-plate enthalpy exchanger possesses the advantages of high recovery effectiveness,low pressure drop,and small space ***,indoor contaminants may transfer to fresh air through the enthalpy exchanger simultaneously,causing cross-contamination ***,the cross-contamination risk of the fixed-plate enthalpy exchanger has been under-researched in previous *** a result,this study experimentally investigates the energy performance,formaldehyde and ammonia transfer rates of paper-based and membrane-based enthalpy *** results illustrate that the enthalpy recovery effectiveness of the plate exchangers ranges from 60%–85%.The formaldehyde transfer rate through the exchangers varies from 5%–23%,and the ammonia transfer rate is 0–15%.The high effectiveness and low contaminant transfer rates are conducive to the promising application of the fixed-plate enthalpy *** addition,the energy reclaimed increases with the increase of the absolute indoor-outdoor enthalpy *** formaldehyde and ammonia transfer rates and cross-contamination risk slightly decrease with increasing temperature but significantly increase with increasing ***,the experimental results demonstrate that the contaminant transfer rates through the membranebased exchanger are lower than those of the paper-based *** study provides a reference for the fixed-plate enthalpy exchanger design in practical applications.

关键词： building energy efficiency enthalpy recovery heat recovery effectiveness cross-contamination

在线全文

学校读者我要写书评

暂无评论

桃仁性味、归经及功效演变的本草考证

中国医药导报 2024年第9期21卷 133-136页

作者：李冉李志鸣周冉冉张艺陶晓华北京中医药大学中医学院北京100029

本文通过查阅历代本草医籍并结合现代文献材料,对桃仁的性味、归经和功效演变进行了系统的梳理与考证。考证结果发现桃仁性味、归经的论述古今确有差异:唐代以前,桃仁味苦、甘、辛,性平、温、热,无毒、双仁者有毒、微毒均有记载,元代首... 详细信息

本文通过查阅历代本草医籍并结合现代文献材料,对桃仁的性味、归经和功效演变进行了系统的梳理与考证。考证结果发现桃仁性味、归经的论述古今确有差异:唐代以前,桃仁味苦、甘、辛,性平、温、热,无毒、双仁者有毒、微毒均有记载,元代首次出现桃仁的归经问题,直至现代桃仁的性味、归经才趋于统一,即苦、甘,平,有小毒,归心、肝、大肠经;在功效演变方面,古今皆用的功效有破血逐瘀、止咳逆、润肠燥。古存今失的功效有辟鬼除邪、杀虫、祛风除蒸等。该研究结果为今后桃仁的深入研究、开发利用等提供本草学依据。

关键词：桃仁性味归经功效考证本草

基于《中医方剂大辞典》挖掘古代治疗偏头痛的用药和时代规律

在线全文

学校读者我要写书评

暂无评论

世界中医药 2024年第1期19卷 69-73,81页

作者：张瑶付兴侯鉴宸周冉冉杨凤李芊芊葛飞罗亚敏陶晓华北京中医药大学中医学院北京102401

目的:通过收集整理《中医方剂大辞典》中治疗偏头痛的古代方剂,挖掘其用药和时代规律,为临床治疗偏头痛提供参考。方法:从《中医方剂大辞典》中筛选出符合标准的方剂,导入古今医案云平台,统计不同时代药物种类、四气、五味、归经和功效... 详细信息

目的:通过收集整理《中医方剂大辞典》中治疗偏头痛的古代方剂,挖掘其用药和时代规律,为临床治疗偏头痛提供参考。方法:从《中医方剂大辞典》中筛选出符合标准的方剂,导入古今医案云平台,统计不同时代药物种类、四气、五味、归经和功效频率,运用复杂网络分析和关联分析挖掘治疗偏头痛的核心中药和药物关联情况。结果:共筛选出266首方剂,涉及337种中药,各年代方药不全相同,但均喜用温性、苦味或辛味,归肺、肝或脾的中药。其中,最核心的中药为川芎、防风和当归,并常用甘草、细辛、防风和川芎相配伍。结论:各年代医家辨治偏头痛用药不尽相同,但其用药思想包括性味归经等基本相同,从汉唐至清代整体一脉相承,总不离祛风、活血、止痛和从肝论治,可为现代临床治疗偏头痛提供重要参考。

关键词：偏头痛数据挖掘中医方剂大辞典古今医案云平台用药规律时代规律关联规则复杂网络